Researchers at King's College London have investigated the properties of over 1,000 approved drugs to identify 2 with potential for Parkinson's.
The results indicate that, when given early, the molecule Anle138b may restore dopamine levels and help slow or stop Parkinson’s in its tracks.
Researchers in the US have launched a clinical trial to test a drug with the potential to slow the progression of Lewy body dementia.
The biotech company Amprion have developed a test to detect the early signs of Parkinson's, before the onset of symptoms, which they hope will be ready to market in the next 18 months.
People with bipolar disorder are almost 7 times more likely to develop Parkinson's than those without the condition, according to new research published in the journal Neurology.
Axovant Gene Therapies Ltd., a company developing innovative gene therapies, has announced they are entering the next stage of a phase II gene therapy trial for Parkinson's.
The STEADY-PD clinical trial has failed to show that isradipine is an effective treatment to slow or stop progression in early Parkinson's.